• Skip to primary navigation
  • Skip to main content
  • Skip to footer

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Who is SAGES?
    • SAGES Mission Statement
    • Advocacy
    • Strategic Plan, 2020-2023
    • Committees
      • Request to Join a SAGES Committee
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Full Committee Rosters
      • SAGES Past Presidents
    • Donate to the SAGES Foundation
    • SAGES Store
    • Awards
      • George Berci Award
      • Pioneer in Surgical Endoscopy
      • Excellence In Clinical Care
      • International Ambassador
      • IRCAD Visiting Fellowship
      • Social Justice and Health Equity
      • Excellence in Community Surgery
      • Distinguished Service
      • Early Career Researcher
      • Researcher in Training
      • Jeff Ponsky Master Educator
      • Excellence in Medical Leadership
      • Barbara Berci Memorial Award
      • Brandeis Scholarship
      • Advocacy Summit
      • RAFT Annual Meeting Abstract Contest and Awards
    • “Unofficial” Logo Products
  • Meetings
    • NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2024 Scientific Session Call For Abstracts
      • 2024 Emerging Technology Call For Abstracts
    • CME Claim Form
    • Industry
      • Advertising Opportunities
      • Exhibit Opportunities
      • Sponsorship Opportunities
    • Future Meetings
    • Related Meetings Calendar
  • Join SAGES!
    • Membership Benefits
    • Membership Applications
      • Active Membership
      • Affiliate Membership
      • Associate Active Membership
      • Candidate Membership
      • International Membership
      • Medical Student Membership
    • Member News
      • Member Spotlight
      • Give the Gift of SAGES Membership
  • Patients
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Patient Information Brochures
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find a SAGES Member
  • Publications
    • SAGES Stories Podcast
    • SAGES Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Patient Information Brochures
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • SCOPE – The SAGES Newsletter
    • COVID-19 Annoucements
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • OpiVoid.org
    • SAGES.TV Video Library
    • Safe Cholecystectomy Program
      • Safe Cholecystectomy Didactic Modules
    • Masters Program
      • SAGES Facebook Program Collaboratives
      • Acute Care Surgery
      • Bariatric
      • Biliary
      • Colorectal
      • Flexible Endoscopy (upper or lower)
      • Foregut
      • Hernia
      • Robotics
    • Educational Opportunities
    • HPB/Solid Organ Program
    • Courses for Residents
      • Advanced Courses
      • Basic Courses
    • Fellows Career Development Course
    • Robotics Fellows Course
    • MIS Fellows Course
    • Facebook Livestreams
    • Free Webinars For Residents
    • SMART Enhanced Recovery Program
    • SAGES OR SAFETY Video
    • SAGES Top 21 MIS Procedures
    • SAGES Pearls
    • SAGES Flexible Endoscopy 101
    • SAGES Tips & Tricks of the Top 21
  • Opportunities
    • NEW-Area of Concentrated Training Seal (ACT)-Advanced Flexible Endoscopy
    • SAGES Fellowship Certification for Advanced GI MIS and Comprehensive Flexible Endoscopy
    • Multi-Society Foregut Fellowship Certification
    • SAGES Research Opportunities
    • Fundamentals of Laparoscopic Surgery
    • Fundamentals of Endoscopic Surgery
    • Fundamental Use of Surgical Energy
    • Job Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
  • OWLS
  • Log In

Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.

Jessica L Campf1, John W Myers1, Guy T Clifton1, Diane F Hale1, Tommy A Brown1, Timothy J Vreeland2, Robert Hi Andtbacka3, Adam C Berger4, James W Jakub5, Jeffrey J Sussman6, Alicia M Terando7, Mark B Faries8. 1San Antonio Military Medical Center, 2University of Texas MD Anderson Cancer Center, 3Huntsman Cancer Institute, 4Thomas Jefferson University Kimmel Cancer Center, 5Mayo Clinic, 6University of Cincinnati Cancer Institute, 7The Ohio State University Cancer Center, 8The Angeles Clinic

Objective: The autologous tumor lysate, particle loaded, dendritic cell (TLPLDC) vaccine has been previously shown to be safe and immunogenic while producing objective tumor responses in a variety of metastatic patients.  Here, we present the pre-specified interim results of a randomized, double blind phase IIb trial (NCT02301611) assessing the TLPLDC vaccine to prevent recurrences in high-risk melanoma patients.

Methods: Stage III & IV resectable melanoma patients were identified prior to definitive surgery and consented for tumor collection.  Patients were re-consented for treatment and randomized 2:1 (vaccine:placebo).  TLPLDC or placebo vaccines were initiated within 3 months of completion of standard of care (SoC) therapies.  Intradermal inoculations were given at 0, 1, 2, 6, 12, and 18 months.  Patients were followed for recurrence per SoC, and the primary endpoint is 2 year disease-free survival (DFS).  The interim analysis was pre-specified at 6 months from the 120th randomization.  Survival analysis was performed on the intention-to-treat (ITT) and per treatment (PT) populations. The latter excludes early recurrences during the primary vaccine series (PVS) (up to 6 months).

Results: The trial randomized 120 patients (Vaccine = 83, Placebo = 37). There were no clinicopathologic or treatment-related differences between the groups except for median age (Vaccine = 65 years, Placebo = 57 years, p=0.02) and ulceration (Vaccine = 11 patients, Placebo = 10 patients, p=0.02).  There was a 3:1 ratio of stage III:IV in both groups.  Study-wide, only 33% of patients experienced treatment-related adverse events (AEs) with 98.6% being grade 1-2.  There were no serious AEs or immune-mediated AEs.

In the ITT analysis, there was no difference in recurrence (Vaccine = 56.6%, Placebo = 54.1%, p=0.65) at a median follow-up of 11.9 months.

In the PT analysis, there was a trend toward decreased recurrences in the TLPLDC arm (Vaccine = 29.4%, Placebo = 43.3%, p=0.07) at a median follow-up of 12.6 months. 

Conclusion: The TLPLDC vaccine is safe with minimal toxicity.  Among patients completing the PVS period (6 months), there is a strong trend toward fewer recurrences in the TLPLDC arm. This benefit will be further elucidated after completion of the analysis of 2 year DFS. Also, this early data provides encouraging results indicating that a phase III trial for efficacy may be warranted.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 94614

Program Number: MSS02

Presentation Session: Full-Day Military Surgical Symposium – Basic Science/Quality Improvement Presentations

Presentation Type: MSSPodium

27

Share this:

  • Twitter
  • Facebook
  • LinkedIn
  • Pinterest
  • WhatsApp
  • Reddit

Related

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064
1-310-437-0544
[email protected]
Monday - Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Facebook
  • Twitter
  • YouTube

Important Links

SAGES 2024 Meeting Information

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals

 

  • taTME Study Info
  • Foundation
  • SAGES.TV
  • MyCME
  • Educational Activities

Copyright © 2023 Society of American Gastrointestinal and Endoscopic Surgeons